Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Valerie Brunt

Clinical Nurse Specialist, Acute Care Madison, MS Nurse Practitioner

NPI 1386029767 CMS profile 10772746

141 Nestling Cv, Madison, MS 39110

Open in the dashboard

General payments

$2,670

139 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Valerie Brunt of Madison, MS is reported in the CMS Open Payments database as having received $2,670 across 139 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Clinical Nurse Specialist, Acute Care profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $220 2
2023 General $559 27
2022 General $1,118 62
2021 General $772 48

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Valerie Brunt
  • Clinical Nurse Specialist, Acute Care median
  • Middle half of Clinical Nurse Specialist, Acute Care
  • National median

In program year 2025, general payments to Valerie Brunt were reported at $220. Among 170 Clinical Nurse Specialist, Acute Care profiles paid that year, the median was $137 and the middle half received between $42 and $436.

Show as a table
Year Valerie Brunt Clinical Nurse Specialist, Acute Care median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $772 $125 $44–$370 $132
2022 $1,118 $109 $56–$356 $149
2023 $559 $126 $43–$435 $160
2024 $0 $128 $46–$385 $164
2025 $220 $137 $42–$436 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Pfizer Inc. $378 26 payments
  2. Janssen Pharmaceuticals, Inc $286 17 payments
  3. Merck Sharp & Dohme Corporation $260 10 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $226 14 payments
  5. Corcept Therapeutics $220 2 payments
  6. iRhythm Technologies, Inc. $197 7 payments
  7. Novartis Pharmaceuticals Corporation $182 9 payments
  8. AstraZeneca Pharmaceuticals LP $162 12 payments
  9. Actelion Pharmaceuticals US, Inc. $161 7 payments
  10. Bayer HealthCare Pharmaceuticals Inc. $147 9 payments
  11. Other $452 26 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $2,670 139 payments
Products named General payments · program years 2021–2025
  1. XARELTO $286 17 payments
  2. VERQUVO $260 10 payments
  3. VYNDAQEL $238 17 payments
  4. JARDIANCE $226 14 payments
  5. Korlym $220 2 payments
  6. ZIO XT Patch $197 7 payments
  7. UPTRAVI $161 7 payments
  8. BRILINTA $147 11 payments
  9. ELIQUIS $140 9 payments
  10. Adempas $101 6 payments
  11. Other $983 55 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

139 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Nurse Specialist, Acute Care in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record